Secondary analysis of baseline DELIVER-MS data (816 treatment-naïve people with relapsing MS): randomised participants had lower relapse rates and greater brain parenchymal fraction than observational ones; 67% of 374 observational participants chose early high-efficacy therapy.
Secondary analysisn = 816
Tallantyre et al. Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)